Next Article in Journal
Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells
Previous Article in Journal
Investigation of Antiinflamatory Effects of Origanum majorana L. Extract in LPS-Induced Beas-2b and A549 Cells
Abstract

Autocrine Growth Hormone (GH)-Mediated Triptolide Resistance Overcame by Metformin Co-Treatment in MDA-MB231 Breast Cancer Cells Through ER Stress Pathway

Department of Molecular Biology and Genetics, Istanbul Kultur University, Atakoy Campus, 34156 Istanbul, Turkey
*
Author to whom correspondence should be addressed.
Presented at the 3rd International conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 18–20 December 2019.
Proceedings 2019, 40(1), 9; https://doi.org/10.3390/proceedings2019040009
Published: 25 December 2019
Breast cancer is the most common cancer in women worldwide and the second most common cancer overall. Autocrine growth hormone (GH) expression induced cell proliferation, growth, invasion-metastasis in vitro and in vivo breast cancer models. Moreover, forced GH signaling acts as a drug resistance profile in breast cancer cell lines against chemotherapeutic drugs such as tamoxifen, mitomycin C, doxorubicin and curcumin. Triptolide, an active plant extract from Tripterygium wilfordii, has been shown to induce apoptotic cell death in various cancer cells such a prostate, colon, breast cancer. Metformin, a common therapeutic agent for type II Diabetes mellitus, has been shown to induce autophagy, endoplasmic reticulum (ER) stress and apoptotic cell death in cancer cells. Our aim is to demonstrate the potential effect of metformin on triptolide-mediated drug resistance in autocrine GH expressing MDA-MB-231 breast cancer cells through Endoplasmic reticulum (ER) stress. Autocrine GH-mediated triptolide (20 nM) resistance overcame by metformin (2 mM) co-teatment in MDA-MB231 breast cancer cells through accelerating cell viability loss, growth inhibition compared to alone triptolide treatment. Combined treatment increased apoptotic cell death via CHOP activation, IRE1α upregulation. Consequently, we suggest that triptolide can be more effective with metformin combination in MDA-MB-231 GH+ drug resistant breast cancer cells.
Keywords: breast cancer; autocrine growth hormone; triptolide; metformin breast cancer; autocrine growth hormone; triptolide; metformin
MDPI and ACS Style

Abdulmunem, A.; Obakan-Yerlikaya, P.; Arisan, E.-D.; Coker-Gurkan, A. Autocrine Growth Hormone (GH)-Mediated Triptolide Resistance Overcame by Metformin Co-Treatment in MDA-MB231 Breast Cancer Cells Through ER Stress Pathway. Proceedings 2019, 40, 9. https://doi.org/10.3390/proceedings2019040009

AMA Style

Abdulmunem A, Obakan-Yerlikaya P, Arisan E-D, Coker-Gurkan A. Autocrine Growth Hormone (GH)-Mediated Triptolide Resistance Overcame by Metformin Co-Treatment in MDA-MB231 Breast Cancer Cells Through ER Stress Pathway. Proceedings. 2019; 40(1):9. https://doi.org/10.3390/proceedings2019040009

Chicago/Turabian Style

Abdulmunem, Amani, Pınar Obakan-Yerlikaya, Elif-Damla Arisan, and Ajda Coker-Gurkan. 2019. "Autocrine Growth Hormone (GH)-Mediated Triptolide Resistance Overcame by Metformin Co-Treatment in MDA-MB231 Breast Cancer Cells Through ER Stress Pathway" Proceedings 40, no. 1: 9. https://doi.org/10.3390/proceedings2019040009

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop